Fairvalue-Calculator Fairvalue-Calculator
EN DE

Beijing Leadman Biochemistry Co (300289) Fair Value & Analysis

Healthcare · CN · Market cap 3.3B CNY

Price¥5.71
Fair Value¥1.70
Upside-70.2%
Quality93/100
Evidence: Medium Range ¥1.17 – ¥1.87

Analysis

Beijing Leadman Biochemistry Co (300289) currently trades at ¥5.71, while our model-based Fair Value estimate is ¥1.70 — implying the stock looks roughly 70.2% overvalued today. We read business quality at 93/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Beijing Leadman Biochemistry Co.,Ltd. researches and develops, manufactures, and sells vitro diagnostic reagents and instruments, and biochemical raw materials in the People's Republic of China. The company offers biochemical raw materials, including enzymes, antigens, coenzymes, antibodies, buffers, enzyme substrates, culture mediums, stain agents, amino acids, and other products for biotechnology, clinical diagnosis, drug development, chemical production, and other related applications. It also provides biochemical reagents for liver function, lipid profile, diabetes reagents, pancreas function, tumor detection, protein and others, multi calibrators and multi co, semi-quantitative assays, coagulation reagents, cardiac marker, cardiac reagents, electrolytes, and renal function; companion reagents regents for tumor, thyroid hormone, sex hormone, infectious disease, and others; and IDS-compatible luminescent reagents. In addition, it offers testing instruments. Beijing Leadman Bioche…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -23% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -9% Boston Scientific Corporation (B1SX34) -11% Edwards Lifesciences Corporation (EW) -53% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.